Skip to main content

Table 1 Results of the meta-analysis for landmark and surveillance MRD in different groups

From: Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

Subgroup analysis

Landmark

Surveillance

TP

FP

FN

TN

Sensitivity

Specificity

AUC

TP

FP

FN

TN

Sensitivity

Specificity

AUC

Lung cancer typeb

Lung cancer (stage I–III)

145

47

213

846

0.41 (0.35–0.46)

0.95 (0.93–0.96)

0.84

178

73

55

467

0.76 (0.70–0.82)

0.86 (0.83–0.89)

0.88

NSCLC (stage I–III)

140

44

205

836

0.41 (0.35–0.46)

0.95 (0.93–0.96)

0.86

169

70

53

460

0.76 (0.70–0.82)

0.87 (0.84–0.90)

0.88

SCLCa

3

3

8

9

0.27 (0.06–0.61)

0.75 (0.43–0.95)

 

9

3

2

6

0.82 (0.48–0.98)

0.67 (0.30–0.93)

 

Stage

Patients at stage I ≥ 50% (NSCLC)

55

25

123

581

0.31 (0.24–0.38)

0.96 (0.94–0.97)

0.81

62

31

21

262

0.75 (0.64–0.84)

0.89 (0.85–0.93)

0.87

Patients at stage I < 50% (NSCLC)

85

19

82

255

0.51 (0.43–0.59)

0.93 (0.89–0.96)

0.90

107

39

32

198

0.77 (0.69–0.84)

0.84 (0.78–0.88)

0.87

Patients at stage I < 50% (lung cancer)

90

22

90

265

0.50 (0.42–0.58)

0.92 (0.89–0.95)

0.88

116

42

34

207

0.77 (0.70–0.84)

0.83 (0.78–0.87)

0.87

Definitive therapy

Surgery (NSCLC)

108

40

197

801

0.35 (0.29–0.40)

0.95 (0.94–0.97)

0.77

153

70

48

449

0.76 (0.70–0.82)

0.87 (0.83–0.89)

0.87

Detection method

Amplicon NGS (NSCLC)

31

7

42

97

0.42 (0.31–0.55)

0.93 (0.87–0.97)

0.43

44

17

13

75

0.77 (0.64–0.87)

0.82 (0.72–0.89)

0.90

Hybrid Capture NGS (NSCLC)

104

32

163

727

0.39 (0.33–0.45)

0.96 (0.94–0.97)

0.88

125

53

40

385

0.76 (0.68–0.82)

0.88 (0.84–0.91)

0.87

Hybrid Capture NGS (lung cancer)

109

35

171

737

0.39 (0.33–0.45)

0.95 (0.94–0.97)

0.85

134

56

42

392

0.76 (0.69–0.82)

0.88 (0.84–0.90)

0.86

Detection strategy

Tumor-informed (NSCLC)

69

27

146

533

0.32 (0.26–0.39)

0.95 (0.93–0.97)

0.78

99

46

44

243

0.69 (0.61–0.77)

0.84 (0.79–0.88)

0.87

Tumor-agnostic (NSCLC)

42

9

27

92

0.61 (0.48–0.72)

0.91 (0.84–0.96)

0.97

29

19

3

33

0.91 (0.75–0.98)

0.63 (0.49–0.76)

0.97

Tumor-agnostic (lung cancer)

47

12

35

102

0.57 (0.46–0.68)

0.89 (0.82–0.94)

0.98

38

22

5

40

0.88 (0.75–0.96)

0.65 (0.51–0.76)

0.94

  1. Abbreviations: TP true positive, FP false positive, FN false negative, TN true negative, AUC area under curve, NA, not applicable
  2. aOnly one SCLC study (stage I–III, stage I ≥ 50%, tumor-agnostic). bAfter using 2 h after surgery as preferred landmark in Peng M’s study, the landmark results changed to: lung cancer (stage I–III): sensitivity: 0.41 (0.36–0.46), specificity: 0.95 (0.93–0.96), AUC: 0.84; NSCLC (stage I–III): sensitivity: 0.41 (0.36–0.47), specificity: 0.95 (0.93–0.96), AUC: 0.86